GSK vs NVS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Jul 06, 2026

GSK

66.2
AI Score
VS
GSK Wins

NVS

58.5
AI Score

Investment Advisor Scores

GSK

66score
Recommendation
BUY

NVS

59score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric GSK NVS Winner
Forward P/E 21.5054 17.452 NVS
PEG Ratio 19.3637 4.1563 NVS
Revenue Growth 1.5% -0.7% GSK
Earnings Growth 8.4% -9.3% GSK
Tradestie Score 66.2/100 58.5/100 GSK
Profit Margin 17.8% 23.9% NVS
Beta 1.00 1.00 Tie
AI Recommendation BUY HOLD GSK

Frequently Asked Questions

Based on our detailed analysis, GSK is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.